<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026011</url>
  </required_header>
  <id_info>
    <org_study_id>NTX-AA</org_study_id>
    <secondary_id>R01AA021744</secondary_id>
    <nct_id>NCT02026011</nct_id>
  </id_info>
  <brief_title>Naltrexone for Individuals of East Asian Descent</brief_title>
  <official_title>Optimizing Naltrexone for Individuals of East Asian Descent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene
      on biobehavioral and neural markers of response to naltrexone in individuals of East Asian
      descent, an ethnic group most likely to express the positive predictive allele.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent pharmacogenetic studies have advanced the gene coding for µ-opioid receptors (OPRM1)
      gene as a potential moderator of responses to naltrexone. The most widely studied
      polymorphism of the OPRM1 gene is the Asn40Asp single nucleotide polymorphism (SNP), a
      functional mutation thought to affect receptor activity such that the Asp40 variant binds
      β-endorphin three times stronger than the Asn40 allele. Recent studies have found that Asp40
      carriers have a stronger striatal dopamine response to intravenous alcohol administration and
      report stronger feelings of alcohol reward. Findings from the COMBINE Study demonstrated that
      if treated with Medication Management alone and naltrexone, 87.1% of Asp40 carriers had a
      good clinical outcome, compared with only 54.8% of Asn40 homozygotes. While these findings
      are promising, studies have also highlighted allele frequency imbalance as a function of
      ethnicity such that the Asp40 allele frequency is approximately 20% in Caucasians, 5% in
      individuals of African Ancestry, and as high as 50% among individuals of East Asian descent.
      Therefore, to the extent to which this SNP moderates behavioral and clinical responses to
      NTX, ethnicity must be carefully considered in order to extend the findings from primarily
      Caucasian samples to ethnic minorities, such as Asian Americans. Preliminary work by our team
      has found that among individuals of East Asian descent, Asp40 carriers show greater
      NTX-induced blunting of alcohol craving as well as potentiation of the aversive effects of
      alcohol. This pilot study also found support for a gene dose-response, such that Asp40Asp
      individuals showed greater NTX responsivity than those with the Asn40Asp genotype. This study
      seeks to build upon these preliminary findings by testing heavy drinkers of East Asian
      descent across three OPRM1 genotypes (Asn40Asn, n = 30; Asn40Asp, n = 30, and Asp40Asp, n =
      30). Participants will complete two double-blinded, counterbalanced alcohol infusion and
      self-administration sessions, one after taking NTX (50 mg/day) and one after taking matched
      placebo for five days. In each medication condition, participants will complete a functional
      neuroimaging task examining cue-induced craving for alcohol. This study will elucidate the
      pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural
      markers of response to naltrexone in individuals of Asian descent, an ethnic group most
      likely to express the positive predictive allele (Asp40). The long-term objective of this
      research is to optimize alcoholism pharmacotherapy and to address health disparities by
      advancing pharmacogenetic studies in ethnic minority groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Response - Craving for Alcohol</measure>
    <time_frame>The AUQ was administered across a period of approximately 1.5 hours.</time_frame>
    <description>Alcohol Urge Questionnaire (AUQ) is used to assess subjective experiences of craving for alcohol. It consists of 8 items, each rated on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). A summary score is used at each assessment time point. The AUQ was administered at baseline and three levels of breath alcohol concentration: 0.02 g/dl. 0.04, g/dl, and 0.06 g/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Response - Stimulation</measure>
    <time_frame>The BAES Stimulant Subscale was administered at baseline and three levels of breath alcohol concentration: 0.2 g/dl. 0.04, g/dl, and 0.06 g/dl taking place within approximately 1.5 hours</time_frame>
    <description>The Biphasic Alcohol Effects Scale (BAES) Stimulant Subscale consists of 14 items designed to capture the stimulant effects of alcohol, rated on an 11-point scale (0 = not at all. 10 = extremely). Total score for the stimulant subscale ranges from 0-70.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Response - Sedation</measure>
    <time_frame>The BAES Sedation Subscale was administered at baseline and three levels of breath alcohol concentration: 0.2 g/dl. 0.04, g/dl, and 0.06 g/dl taking place within approximately 1.5 hours</time_frame>
    <description>The Biphasic Alcohol Effects Scale (BAES) Sedation Subscale consists of 14 items designed to capture the sedating effects of alcohol, rated on an 11-point scale (0 = not at all. 10 = extremely). Total score for the sedation subscale ranges from 0-70.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural Response to Alcohol Cues</measure>
    <time_frame>During the alcohol cue exposure fMRI paradigm which is expected to last 45 minutes</time_frame>
    <description>Alcohol taste cues task for functional magnetic resonance imaging (fMRI). Region of Interest (ROI) were atomically defined using the Harvard-Oxford atlas in standard Montreal Neurological Institute (MNI) space, which were transformed into individual participants' native space using Functional Magnetic Resonance Imaging of the Brain Software Library (FSL). Contrast estimates are for Alc &gt; Water cue, and are arbitrary units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol Self-administration - Number of Drinks</measure>
    <time_frame>Alcohol self-administration period was 1 hour long</time_frame>
    <description>Total number of drinks consumed during the alcohol self-administration task</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 50 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Revia</other_name>
    <other_name>Depade</other_name>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill, matched to the active study medication in capsule size and color</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current (i.e., past month) alcohol dependence

          -  East Asian ethnicity (i.e., Chinese, Korean, or Japanese)

          -  Prospective genotyping for the A118G SNP of the mu opioid receptor (OPRM1) gene to
             allow for balanced groups on all three genotypes (AA, AG, GG)

        Exclusion Criteria:

          -  lifetime DSM-IV of drug dependence (other than alcohol or nicotine)

          -  current use of psychoactive drugs as determined by self-reports and verified using
             toxicology testing

          -  lifetime diagnosis of bipolar disorder or any psychotic disorder

          -  contraindications to an MRI scan (including left handedness)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara Ray, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Addictions Laboratory</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://addictions.psych.ucla.edu</url>
    <description>UCLA Addictions Laboratory</description>
  </link>
  <reference>
    <citation>Ray LA, Bujarski S, Chin PF, Miotto K. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology. 2012 Jan;37(2):445-55. doi: 10.1038/npp.2011.192. Epub 2011 Sep 7.</citation>
    <PMID>21900886</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <results_first_submitted>January 8, 2019</results_first_submitted>
  <results_first_submitted_qc>June 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2019</results_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Lara Ray, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>alcohol use disorder</keyword>
  <keyword>naltrexone</keyword>
  <keyword>Asian American</keyword>
  <keyword>pharmacogenetics</keyword>
  <keyword>OPRM1 gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 199 individuals were screened in the laboratory, of those 106 completed the physical exam, and of those 87 were eligible and agreed to be randomized. Participants received in random order either Naltrexone (titrated up to 50 mg/day) or Placebo at each Allocation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Allocated to Naltrexone</title>
          <description>Group that was randomly assigned to receive Naltrexone first.</description>
        </group>
        <group group_id="P2">
          <title>Allocated to Placebo</title>
          <description>Group that was randomly assigned to receive Placebo first</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Allocation 1 (First Set of Medication)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Side Effects</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Allocation 2 (Second Set of Medication)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Providing baseline data for the 77 individuals who completed at least one experimental session</population>
      <group_list>
        <group group_id="B1">
          <title>Asn40Asn Genotype</title>
          <description>Group that is homozygotes for the Asn40 allele</description>
        </group>
        <group group_id="B2">
          <title>Asn40asp/Asp40Asp Genotype</title>
          <description>Group that is a carrier of the Asp40 allele</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.72" spread="7.57"/>
                    <measurement group_id="B2" value="25.69" spread="4.84"/>
                    <measurement group_id="B3" value="26.83" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Chinese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japanese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Korean</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Taiwanese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use Disorder Identification Test (AUDIT)</title>
          <description>Alcohol Use Disorder Identification Test (AUDIT) developed by the World Health Organization. The AUDIT is a 10 item measure from which you can calculate a total score ranging from 0 to 40. Higher scores indicate more hazardous drinking. A score = or &gt; than 8 indicates a hazardous drinking pattern.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.14" spread="5.82"/>
                    <measurement group_id="B2" value="13.17" spread="4.83"/>
                    <measurement group_id="B3" value="14.29" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Response - Craving for Alcohol</title>
        <description>Alcohol Urge Questionnaire (AUQ) is used to assess subjective experiences of craving for alcohol. It consists of 8 items, each rated on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). A summary score is used at each assessment time point. The AUQ was administered at baseline and three levels of breath alcohol concentration: 0.02 g/dl. 0.04, g/dl, and 0.06 g/dl.</description>
        <time_frame>The AUQ was administered across a period of approximately 1.5 hours.</time_frame>
        <population>Participants who completed at least one experimental session.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - Asn40Asn</title>
            <description>Group that was randomized to receive Naltrexone (50 mg/d) and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Naltrexone (50mg/d) and carries at least one copy of the Asp40 allele.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Asn40Asn</title>
            <description>The group that was randomized to receive placebo and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Placebo and carries at least one copy of the Asp40 allele.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Response - Craving for Alcohol</title>
          <description>Alcohol Urge Questionnaire (AUQ) is used to assess subjective experiences of craving for alcohol. It consists of 8 items, each rated on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). A summary score is used at each assessment time point. The AUQ was administered at baseline and three levels of breath alcohol concentration: 0.02 g/dl. 0.04, g/dl, and 0.06 g/dl.</description>
          <population>Participants who completed at least one experimental session.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BrAC = 0.02 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7037" spread="0.9295"/>
                    <measurement group_id="O2" value="1.9965" spread="1.2862"/>
                    <measurement group_id="O3" value="2.1012" spread="1.2881"/>
                    <measurement group_id="O4" value="1.8478" spread="0.9812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BrAC = 0.04 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9198" spread="1.1260"/>
                    <measurement group_id="O2" value="2.1319" spread="1.3024"/>
                    <measurement group_id="O3" value="2.3095" spread="1.4499"/>
                    <measurement group_id="O4" value="2.2645" spread="1.2311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BrAc = 0.06 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0185" spread="1.3590"/>
                    <measurement group_id="O2" value="2.2014" spread="1.3430"/>
                    <measurement group_id="O3" value="2.3095" spread="1.4400"/>
                    <measurement group_id="O4" value="2.4891" spread="1.4595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>Medication effect: b = -0.15, SE = 0.17, t = -0.86, p = 0.39</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>Genotype effect: b = 0.20, SE = 0.21, t = 0.96, p = 0.34</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>BrAC effect: b = 0.13, SE = 0.06, t = 2.10, p = 0.04</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <p_value_desc>Medication by genotype interaction: b = 0.15, SE = 0.21, t = 0.73, p = 0.47</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>Medication by genotype by BrAC interaction: b = -0.20, SE = 0.13, t = -1.52, p = 0.13</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Response - Stimulation</title>
        <description>The Biphasic Alcohol Effects Scale (BAES) Stimulant Subscale consists of 14 items designed to capture the stimulant effects of alcohol, rated on an 11-point scale (0 = not at all. 10 = extremely). Total score for the stimulant subscale ranges from 0-70.</description>
        <time_frame>The BAES Stimulant Subscale was administered at baseline and three levels of breath alcohol concentration: 0.2 g/dl. 0.04, g/dl, and 0.06 g/dl taking place within approximately 1.5 hours</time_frame>
        <population>Participants who completed at least one experimental session.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - Asn40Asn</title>
            <description>Group that was randomized to receive Naltrexone (50 mg/d) and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Naltrexone (50mg/d) and carries at least one copy of the Asp40 allele.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Asn40Asn</title>
            <description>The group that was randomized to receive placebo first and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Placebo and carries at least one copy of the Asp40 allele.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Response - Stimulation</title>
          <description>The Biphasic Alcohol Effects Scale (BAES) Stimulant Subscale consists of 14 items designed to capture the stimulant effects of alcohol, rated on an 11-point scale (0 = not at all. 10 = extremely). Total score for the stimulant subscale ranges from 0-70.</description>
          <population>Participants who completed at least one experimental session.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BrAC = 0.02 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0423" spread="1.7338"/>
                    <measurement group_id="O2" value="2.0893" spread="1.8291"/>
                    <measurement group_id="O3" value="2.0102" spread="1.9867"/>
                    <measurement group_id="O4" value="1.8106" spread="1.7512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BrAC = 0.04 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2963" spread="1.8860"/>
                    <measurement group_id="O2" value="2.7679" spread="1.9415"/>
                    <measurement group_id="O3" value="2.3316" spread="2.0949"/>
                    <measurement group_id="O4" value="2.4658" spread="1.9971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BrAc = 0.06 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8307" spread="2.3581"/>
                    <measurement group_id="O2" value="3.0149" spread="2.1955"/>
                    <measurement group_id="O3" value="2.2347" spread="1.9917"/>
                    <measurement group_id="O4" value="3.0466" spread="2.4146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>Medication effect: b = 0.16, SE = 0.13, t = 1.20, p = 0.23</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>Genotype effect: b = 0.37, SE = 0.22, t = 1.69, p = 0.09</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <p_value_desc>Medication by genotype interaction: b = 0.04, SE = 0.21, t = 0.20, p = 0.84</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Medication by genotype by BrAC interaction: b = -0.32, SE = 0.16, t = -1.93, p = 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Response - Sedation</title>
        <description>The Biphasic Alcohol Effects Scale (BAES) Sedation Subscale consists of 14 items designed to capture the sedating effects of alcohol, rated on an 11-point scale (0 = not at all. 10 = extremely). Total score for the sedation subscale ranges from 0-70.</description>
        <time_frame>The BAES Sedation Subscale was administered at baseline and three levels of breath alcohol concentration: 0.2 g/dl. 0.04, g/dl, and 0.06 g/dl taking place within approximately 1.5 hours</time_frame>
        <population>Participants who completed at least one experimental session.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - Asn40Asn</title>
            <description>Group that was randomized to receive Naltrexone (50 mg/d) and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Naltrexone (50mg/d) and carries at least one copy of the Asp40 allele.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Asn40Asn</title>
            <description>The group that was randomized to receive placebo and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Placebo and carries at least one copy of the Asp40 allele.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Response - Sedation</title>
          <description>The Biphasic Alcohol Effects Scale (BAES) Sedation Subscale consists of 14 items designed to capture the sedating effects of alcohol, rated on an 11-point scale (0 = not at all. 10 = extremely). Total score for the sedation subscale ranges from 0-70.</description>
          <population>Participants who completed at least one experimental session.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BrAC = 0.02 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6825" spread="2.1146"/>
                    <measurement group_id="O2" value="2.3482" spread="1.6194"/>
                    <measurement group_id="O3" value="2.1480" spread="1.6452"/>
                    <measurement group_id="O4" value="2.0560" spread="1.6726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BrAC = 0.04 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8571" spread="2.1907"/>
                    <measurement group_id="O2" value="2.8601" spread="2.0094"/>
                    <measurement group_id="O3" value="2.4949" spread="1.7798"/>
                    <measurement group_id="O4" value="2.6832" spread="1.8504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BrAc = 0.06 g/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0688" spread="2.4364"/>
                    <measurement group_id="O2" value="3.1548" spread="2.0981"/>
                    <measurement group_id="O3" value="2.6786" spread="2.4767"/>
                    <measurement group_id="O4" value="2.4627" spread="1.8025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>Medication effect: b = 0.14, SE = 0.23, t = 0.61, p = 0.55</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <p_value_desc>Genotype effect: b = -0.11, SE = 0.37, t = -0.30, p = 0.77</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>BrAC effect: b = 0.30, SE = 0.15, t = 2.02, p = 0.04</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <p_value_desc>Medication by genotype interaction: b = -0.21, SE = 0.29, t = -0.72, p = 0.47</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>Medication by genotype by BrAC interaction: b = 0.28, SE = 0.21, t = 1.30, p = 0.19</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neural Response to Alcohol Cues</title>
        <description>Alcohol taste cues task for functional magnetic resonance imaging (fMRI). Region of Interest (ROI) were atomically defined using the Harvard-Oxford atlas in standard Montreal Neurological Institute (MNI) space, which were transformed into individual participants' native space using Functional Magnetic Resonance Imaging of the Brain Software Library (FSL). Contrast estimates are for Alc &gt; Water cue, and are arbitrary units.</description>
        <time_frame>During the alcohol cue exposure fMRI paradigm which is expected to last 45 minutes</time_frame>
        <population>Participants who completed at least one experimental session and whose neuroimaging data was not excluded due to excessive motion (&gt;2 mm translation) and/or poor registration.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - Asn40Asn</title>
            <description>Group that was randomized to receive Naltrexone (50 mg/d) and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Naltrexone (50mg/d) and carries at least one copy of the Asp40 allele.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Asn40Asn</title>
            <description>The group that was randomized to receive placebo and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Placebo and carries at least one copy of the Asp40 allele.</description>
          </group>
        </group_list>
        <measure>
          <title>Neural Response to Alcohol Cues</title>
          <description>Alcohol taste cues task for functional magnetic resonance imaging (fMRI). Region of Interest (ROI) were atomically defined using the Harvard-Oxford atlas in standard Montreal Neurological Institute (MNI) space, which were transformed into individual participants' native space using Functional Magnetic Resonance Imaging of the Brain Software Library (FSL). Contrast estimates are for Alc &gt; Water cue, and are arbitrary units.</description>
          <population>Participants who completed at least one experimental session and whose neuroimaging data was not excluded due to excessive motion (&gt;2 mm translation) and/or poor registration.</population>
          <units>Mean contrast estimate for Alc&gt;Water cue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ventral Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="19.94"/>
                    <measurement group_id="O2" value="8.07" spread="13.95"/>
                    <measurement group_id="O3" value=".53" spread="13.47"/>
                    <measurement group_id="O4" value="1.03" spread="13.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orbitofrontal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".12" spread="11.75"/>
                    <measurement group_id="O2" value="4.43" spread="9.64"/>
                    <measurement group_id="O3" value=".45" spread="7.2"/>
                    <measurement group_id="O4" value="3.56" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="17.96"/>
                    <measurement group_id="O2" value="7.04" spread="13.90"/>
                    <measurement group_id="O3" value="5.17" spread="14.24"/>
                    <measurement group_id="O4" value="9.49" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Self-administration - Number of Drinks</title>
        <description>Total number of drinks consumed during the alcohol self-administration task</description>
        <time_frame>Alcohol self-administration period was 1 hour long</time_frame>
        <population>Participants who completed at least one experimental session.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - Asn40Asn</title>
            <description>Group that was randomized to receive Naltrexone (50 mg/d) and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Naltrexone (50mg/d) and carries at least one copy of the Asp40 allele.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Asn40Asn</title>
            <description>The group that was randomized to receive placebo and is homozygote for the Asn40 allele.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Asn40Asp/Asp40Asp</title>
            <description>Group that was randomized to receive Placebo and carries at least one copy of the Asp40 allele.</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Self-administration - Number of Drinks</title>
          <description>Total number of drinks consumed during the alcohol self-administration task</description>
          <population>Participants who completed at least one experimental session.</population>
          <units>drinks consumed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4444" spread="1.5275"/>
                    <measurement group_id="O2" value="0.6458" spread="1.1576"/>
                    <measurement group_id="O3" value="1.5714" spread="1.4764"/>
                    <measurement group_id="O4" value="0.9565" spread="1.3656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>Medication effect: F(1,71) = 2.24, p = 0.14</p_value_desc>
            <method>Poisson Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>Genotype effect: F(1, 71) = 5.79, p = 0.02</p_value_desc>
            <method>Poisson</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>Medication by genotype interaction: F(1, 70) = 0.68, p = 0.41.</p_value_desc>
            <method>Poisson</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected immediately prior to alcohol infusion while on naltrexone and while on placebo (2 time points). This data was collected twice for each participant, once while they were on placebo and once while they were on naltrexone.</time_frame>
      <desc>Adverse events are defined as any symptom endorsed on the Side Effects Checklist (SAFTEE). The instructions on the SAFTEE are, &quot;Have you noticed any of the following symptoms within the last 6 hours? If yes, how severe were the symptoms? Do you believe these symptoms were caused by the study medication?&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone</title>
          <description>Naltrexone 50 mg/day
Naltrexone: Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Matched placebo
Placebo: Sugar pill, matched to the active study medication in capsule size and color</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Yellow Eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or cramps</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea or vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability or anger</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Increased desire for sex</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Ringing in the ears</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Decrease in appetite</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Difficulty in staying awake</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Increase in appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Mental confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Joint or muscle pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Sexual problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fever or chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Decreased desire for sex</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lara Ray</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>310-794-5383</phone>
      <email>lararay@psych.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

